ORMP

Oramed Pharmaceuticals Inc

ORMP, USA

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.

https://www.oramed.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
ORMP
stock
ORMP

Portfolio Shifts: How buybacks impact ORMP stock value - 2025 Volatility Report & Low Risk Investment Opportunities moha.gov.vn

Read more →
ORMP
stock
ORMP

Oramed declares dividend distribution of common stock purchase rights MSN

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

HOLD

Target Price:

$3.25

Analyst Picks

Strong Buy

0

Buy

0

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very High

2.75

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very Low

0.60

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very High

23.81 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very High

21.95 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.09

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 18.17% of the total shares of Oramed Pharmaceuticals Inc

1.

BML Capital Management LLC

(7.5195%)

since

2025/06/30

2.

Murchinson Ltd.

(4.2717%)

since

2025/06/30

3.

BOOTHBAY FUND MANAGEMENT, LLC

(2.0617%)

since

2025/06/30

4.

Rathbone Brothers PLC

(0.5683%)

since

2025/06/30

5.

Dimensional Fund Advisors, Inc.

(0.407%)

since

2025/06/30

6.

Renaissance Technologies Corp

(0.3517%)

since

2025/06/30

7.

Bank of America Corp

(0.3497%)

since

2025/06/30

8.

Citadel Advisors Llc

(0.2129%)

since

2025/06/30

9.

BlackRock Inc

(0.2087%)

since

2025/06/30

10.

Peapod Lane Capital LLC

(0.2068%)

since

2025/06/30

11.

iShares Micro-Cap ETF

(0.1901%)

since

2025/08/31

12.

State Street Corp

(0.1621%)

since

2025/06/30

13.

Connor Clark & Lunn Inv Mgmt Ltd

(0.1474%)

since

2025/06/30

14.

SPDR® Portfolio Developed Wld ex-US ETF

(0.1386%)

since

2025/08/29

15.

Susquehanna International Group, LLP

(0.1181%)

since

2025/06/30

16.

Royal Bank of Canada

(0.1161%)

since

2025/06/30

17.

Squarepoint Ops LLC

(0.1124%)

since

2025/06/30

18.

RBC Microcap Value I

(0.1105%)

since

2025/06/30

19.

RBF LLC

(0.1047%)

since

2025/06/30

20.

Jane Street Group LLC

(0.1033%)

since

2025/06/30

21.

Dimensional US Core Equity 2 ETF

(0.0891%)

since

2025/08/29

22.

Morgan Stanley - Brokerage Accounts

(0.0783%)

since

2025/06/30

23.

Geode Capital Management, LLC

(0.0592%)

since

2025/06/30

24.

Fidelity Nasdaq Composite Index

(0.0592%)

since

2025/07/31

25.

Dimensional US Targeted Value ETF

(0.0587%)

since

2025/08/29

26.

DFA US Core Equity 2 I

(0.0569%)

since

2025/07/31

27.

PNC Financial Services Group Inc

(0.0566%)

since

2025/06/30

28.

Avantis US Small Cap Equity ETF

(0.0377%)

since

2025/08/30

29.

DFA US Targeted Value I

(0.0338%)

since

2025/07/31

31.

Dimensional Global Trgtd Value USD Acc

(0.0258%)

since

2025/07/31

32.

Dimensional Global Core Equity USD Acc

(0.0206%)

since

2025/06/30

33.

1290 VT Micro Cap K

(0.0171%)

since

2025/07/31

34.

Dimensional US Small Cap ETF

(0.0159%)

since

2025/08/29

35.

DFA US Social Core Equity 2 Portfolio

(0.012%)

since

2025/07/31

36.

Dimensional Global Small Coms USD Acc

(0.0116%)

since

2025/06/30

37.

DFA US Core Equity Class F

(0.0113%)

since

2025/06/30

38.

Dimensional US Core Equity 1 ETF

(0.011%)

since

2025/08/29

39.

Dimensional World Allc 60/40 GBP Acc

(0.0108%)

since

2025/07/31

40.

Dimensional World Equity GBP Acc

(0.0106%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.08

Latest Release

Date

2025-09-30

EPS Actual

1.13

EPS Estimate

-0.04

EPS Difference

1.17

Surprise Percent

2925%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(8.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Wide Moat Company(9)
GARP
Fair GARP(6)
Growth
Moderate Growth(4)
Momentum
No Momentum(3)
Net Net
Possible Net-Net(5)
Quality
High Quality(6.5)
Value
Undervalued(10)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.